AstraZeneca receives CDSCO panel nod to conduct phase 3 trial of Trastuzumab Deruxtecan - Video
|
Overview
In a significant development, major drug-maker AstraZeneca has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase 3 clinical trial of oncology drug Trastuzumab Deruxtecan, which is an antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
This comes in the wake of the Phase III clinical trial protocol presented by AstraZeneca at the recent SEC meeting for Oncology and Haematology.
For more details, check out the full story on the link below:
AstraZeneca Gets CDSCO Panel Nod To Conduct Cancer Drug Trastuzumab Deruxtecan Study
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
